Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-02-11
1995-10-03
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514438, 514444, 514452, 514461, 514464, 514471, 514510, 514531, 514546, 514569, 514617, 514684, 514700, 514719, 514717, 514729, 514765, 549 60, 549 70, 549'71, 549 72, 549 73, 549 74, 549 75, 549 77, 549 78, 549 79, 549 80, 549369, 549370, 549430, 549448, 549468, 549483, 549486, 549487, 549493, 549495, 549496, 549497, 549498, 549499, 549501, 549504, 549505, 549506, 560 8, 560100, 562405, 562490, 564180, 568327, 568328, 568440, 568592, 568659, 568808, 585 20, 585 21, H61K 3119, H61K 3134, H61K 3138
Patent
active
054552656
ABSTRACT:
Process of treatment of mammals, including humans to treat diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid receptor sites in preference to the RAR retinoid receptor sites. A compound is defined to be a selective agonist of the RXR receptor site if the compound is at least approximately ten times more effective as an agonist in the RXR receptor sites than in the RAR receptor sites.
REFERENCES:
patent: 4096341 (1978-06-01), Frazer
patent: 4326055 (1982-04-01), Loeligen
patent: 4391731 (1983-07-01), Boller et al.
patent: 4695649 (1987-09-01), Magami et al.
patent: 4723028 (1988-02-01), Shado
patent: 4739098 (1988-04-01), Chandraratna
patent: 4740519 (1988-04-01), Shroot et al.
patent: 4808597 (1989-02-01), Hoffman et al.
patent: 4810804 (1989-03-01), Chandraratna
patent: 4826969 (1989-05-01), Maignan et al.
patent: 4826984 (1989-05-01), Berlin et al.
patent: 4855320 (1989-08-01), Chatterjee et al.
patent: 4876349 (1989-10-01), Klaus et al.
patent: 4895868 (1990-01-01), Chandraratna
patent: 4923884 (1990-05-01), Chandraratna
patent: 4931458 (1990-06-01), Klaus et al.
patent: 4980369 (1990-12-01), Chandraratna
patent: 4992468 (1991-02-01), Chandraratna
patent: 5006550 (1991-04-01), Chandraratna
patent: 5013744 (1991-05-01), Chandraratna
patent: 5015658 (1991-05-01), Chandraratna
patent: 5023341 (1991-06-01), Chandraratna
patent: 5037825 (1991-08-01), Klaus et al.
patent: 5045551 (1991-09-01), Chandraratna
patent: 5053523 (1991-10-01), Chandraratna
patent: 5068252 (1991-11-01), Chandraratna
patent: 5089509 (1992-02-01), Chandraratna
patent: 5130355 (1992-07-01), Chandraratna et al.
patent: 5134159 (1992-07-01), Chandraratna
patent: 5162546 (1992-11-01), Chandraratna
patent: 5175185 (1992-12-01), Chandraratna
patent: 5183827 (1993-02-01), Chandraratna
patent: 5202471 (1993-04-01), Chandraratna
Hoffmann, Sandra L., M.D. "Retinoids--`Differentiation Agents` for Cancer Treatment and Prevention", Am. J. Med. Sci., vol. 304, No. 3, 1992, pp. 202-231.
Aneskievich, et al., "Terminal Differentiation in Keratinocytes Involves Positive as well as Negative Regulation by Retinoid Acid Receptors and Retinoid X Receptors at Retinoid Response Elements", Mol. Cell. Biol., vol. 12, No. 11, 1992, pp. 4862-4871.
A General Synthesis of Terminal and Internal Arylalkynes by the Palladium-Catalyzed Reaction of Alkynylzinc Reagents with Aryl Halides by Anthony O. King and Ei-ichi Negishi, J. Org. Chem. 43 No. 2, 1978, p. 358.
Conversion of Methyl Ketones into Terminal Acetylenes and (E)-Trisubstituted Olefins of Terpenoid Origin by Ei-ichi, Anthony O. King, and William L. Klima, J. Org. Chem. 45 No. 12, 1980 p. 2526.
Sporn et al. in J. Amer. Acad. Derm. 15:756-764 (1986).
A Convenient Synthesis of Ethynylarenes and Diethynylarenes by S. Takahashi, Y. Kuroyama, K. Sonogashira, N. Hagihara, Snthesis 1980 pp. 627-630.
Shudo et al. in Chem. Phar. Bull. 33:404-407 (1985).
Kagechika et al. in J. Med. Chem. 31:2182-2192 (1988).
Chemistry and Biology of Synthetic Retinoids by Marcia I. Dawson and William H. Okamura, published by CRC Press Inc., 1990, pp. 334-335, 354.
Snthesis of 2,2'-Diacyl-1,1'-biaryls. Regiocontrolled Protection of . . . by Mervic, et al, J. Org. Chem., No. 45, pp. 4720-4725, 1980.
A Dopamine Receptor Model and Its Application in the Design of a New Class of Rigid Pyrrolo]2,3-g]isoquinoline Antipsychotics, Gary L. Olson, et al., American Chemical Society, 1981, vol. 24, No. 9, pp. 1026-1031.
6.2.3 Conformational Restriction, Williams, et al., Drug Discovery and Development, 1987 The Humana Press, pp. 54-55.
V. Retinoid Structure-Biological Activity Relationships, Chemistry and Biology of Synthetic Retinoids, pp. 324-356 (1990).
J. M. Lehmann, et al, Retinoids Selective for Retinoid X Receptor Response Pathways, Science, vol. 258, 18 Dec. 1992, pp. 1944-1946.
Ney et al, Chemical Abstracts, vol. 108 (1987) 68312g.
Allergan Inc.
Baran Robert J.
Raymond Richard L.
Szekeres Gabor L.
Voet Martin A.
LandOfFree
Method of treatment with compounds having selective agonist-like does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment with compounds having selective agonist-like, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment with compounds having selective agonist-like will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1077761